How much is my risk of clozapine-induced agranulocytosis affected by these variants?
The overall risk of CIA has been reported to be 0.4% under the current blood monitoring system in the absence of pharmacogenetic testing. However, with this pharmacogenetic test, we can more precisely determine your individual risk. Your risk of developing clozapine-induced agranulocytosis is approximately 20% lower than the overall patient population if you are in the Lower Risk group. Patients who fall into the Higher Risk group have a risk of CIA that is approximately 1175% higher than the overall patient population.
Related Questions
- If my patient’s test results indicate that s/he is at Lower Risk of developing clozapine-induced agranulocytosis, is it necessary to continue weekly blood monitoring?
- If my test results indicate that I am at Lower Risk of developing clozapine-induced agranulocytosis, do I need to continue to undergo weekly blood monitoring?
- How much is my risk of clozapine-induced agranulocytosis affected by these variants?
